Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers J > Headlines for Johnson & Johnson Inc. > News item |
Cordis study suggests drug-eluting stent, size important reblockage predictors
By Elaine Rigoli
Tampa, Fla., May 16 - A comprehensive analysis concluded that vessel size and use of the Taxus stent are the two most important predictors of reblockage (restenosis) and the need for repeat revascularization, Cordis said Tuesday.
The study also concluded that use of the Taxus stent impacted restenosis in small coronary vessels.
Cordis, a Johnson & Johnson company, develops interventional vascular technology.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.